PKO Investment Management Joint Stock Co Acquires 4,500 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

PKO Investment Management Joint Stock Co boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 41.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 15,300 shares of the biopharmaceutical company’s stock after buying an additional 4,500 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.1% of PKO Investment Management Joint Stock Co’s holdings, making the stock its 21st biggest holding. PKO Investment Management Joint Stock Co’s holdings in Regeneron Pharmaceuticals were worth $9,704,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of REGN. Capital International Investors lifted its stake in Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares in the last quarter. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $802,036,000. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after purchasing an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Finally, Amundi lifted its position in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 22nd. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. Wells Fargo & Company cut Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $700.00 to $580.00 in a report on Friday, May 30th. UBS Group lowered their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating on the stock in a research report on Thursday, June 5th. Finally, Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating for the company in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $836.48.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $522.68 on Tuesday. The company has a market cap of $56.43 billion, a P/E ratio of 13.65, a P/E/G ratio of 2.34 and a beta of 0.31. The firm’s fifty day moving average price is $562.50 and its two-hundred day moving average price is $646.92. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm posted $9.55 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.